About 1ST Biotherapeutics
1ST Bio is dedicated to developing breakthrough therapies with a key value to provide novel medicines to patients. We are focused on discovery and development of innovative first-in-class therapeutic candidates with highly likelihood of clinical success.
Founder and CEO: Jamie Jae Eun Kim
1 article with 1ST Biotherapeutics
1ST Bio today announced a collaboration to co-develop novel brain penetrant c-Abl inhibitors for Parkinson's disease.